Dr Neeltje Steeghs is the Director of Phase I studies and Clinical Research at the Netherlands Cancer Institute.
Dr Steeghs has a firm background in clinical research and has subspecialty interests in sarcoma, targeted agents and therapeutic drug monitoring. She is a licensed medical oncologist and clinical pharmacologist.
She has been principle investigator for many investigator initiated and industry sponsored clinical trials and has published over 65 peer-reviewed articles in journals. She is regarded as a leading authority on mechanisms for safe and effective dosing of anticancer agents. Current research interests include early drug development, therapeutic monitoring of anti-cancer agents, drug imaging and drug-drug interaction studies.